optimizing treatment options for her2 / er breast cancer using models of endocrine resistance
Published 5 years ago • 17K plays • Length 51:40Download video MP4
Download video MP3
Similar videos
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
52:21
new & supporting data for optimizing therapy in her2 breast cancer | dr. irene and dr. vogel
-
8:47
sramila aithal, md | neratinib and dose escalation | optimizing therapy for her2 disease
-
6:48
how to use endocrine therapy in premenopausal women with er early breast cancer
-
1:27
treating er breast cancer patients with endocrine therapy resistance
-
51:56
new & supporting data for optimizing therapy in her2 breast cancer | dr. kaklamani and dr. o’regan
-
7:18
optimising treatment selection for patients with er /her2- breast cancer
-
55:48
new & supporting data for optimizing therapy in her2 breast cancer | dr. bagegni & dr. gradishar
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
5:00
adjuvant endocrine therapy used to treat er her2- breast cancer
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
1:26
dr. burstein on adjuvant endocrine therapy for er breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
1:14
endocrine therapy resistance in er metastatic breast cancer